Jim Aizire1, Kristina M Brooks2, Mark Mirochnick3, Patricia M Flynn4, Kevin Butler5, Jennifer J Kiser2, George K Siberry6, Terry Fenton5, Mae Cababasay5, Mary G Fowler7. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 2. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO. 3. Division of Neonatology, School of Medicine, Boston University, Boston, MA. 4. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN. 5. Harvard T. H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA. 6. Division of Prevention, Care & Treatment, Office of HIV/AIDS, United States Agency for International Development (USAID), Arlington, VA; and. 7. Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, tenofovir disoproxil fumarate (TDF) use was associated with moderate or severe adverse pregnancy/neonatal outcomes. This study characterized tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) concentrations in dried blood spots (DBS) and assessed association between severe adverse pregnancy/neonatal outcomes and TFV-DP concentration. METHODS: Retrospective case-control study of PROMISE trial arm-C women randomized to receive TDF, FTC, and ritonavir-boosted lopinavir (LPV/r), who took at least 1 dose of TDF + FTC and had week-4 postrandomization DBS drawn before delivery. Cases, defined as severe adverse pregnancy/neonatal outcomes (very preterm delivery before 34 weeks of gestation, stillbirth ≥20 weeks of gestation, or infant death before 14 days-of-age), were matched to controls (1:2 ratio) by site and gestational age at entry. Week 4 and week 8 DBS samples were assayed for TFV-DP and FTC-TP by liquid chromatography and tandem mass spectrometry. Associations were tested using Wilcoxon rank test and conditional logistic regression. RESULTS: Of 447 PROMISE arm-C women, 33 met case definitions, and overall, 22 cases and 44 controls were analyzed. Median (interquartile range) concentrations of TFV-DP at weeks 4 and 8 were 706 (375-1023) fmol/punch and 806 (414-1265) fmol/punch, respectively. Odds ratio (95% confidence interval) for severe adverse pregnancy/neonatal outcome with natural log of TFV-DP concentrations as the predictor were 1.27 (0.74 to 2.18) and 1.74 (0.66 to 4.60) at weeks 4 and 8, respectively. Median (interquartile range) concentrations of FTC-TP at weeks 4 and 8 were 0.27 (0.05-0.36) pmol/punch and 0.29 (0.05-0.40) pmol/punch, respectively. CONCLUSIONS: TFV-DP concentrations in DBS appeared not to be associated with severe adverse pregnancy/neonatal outcomes, although sample size was limited.
BACKGROUND: In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, tenofovir disoproxil fumarate (TDF) use was associated with moderate or severe adverse pregnancy/neonatal outcomes. This study characterized tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) concentrations in dried blood spots (DBS) and assessed association between severe adverse pregnancy/neonatal outcomes and TFV-DP concentration. METHODS: Retrospective case-control study of PROMISE trial arm-C women randomized to receive TDF, FTC, and ritonavir-boosted lopinavir (LPV/r), who took at least 1 dose of TDF + FTC and had week-4 postrandomization DBS drawn before delivery. Cases, defined as severe adverse pregnancy/neonatal outcomes (very preterm delivery before 34 weeks of gestation, stillbirth ≥20 weeks of gestation, or infant death before 14 days-of-age), were matched to controls (1:2 ratio) by site and gestational age at entry. Week 4 and week 8 DBS samples were assayed for TFV-DP and FTC-TP by liquid chromatography and tandem mass spectrometry. Associations were tested using Wilcoxon rank test and conditional logistic regression. RESULTS: Of 447 PROMISE arm-C women, 33 met case definitions, and overall, 22 cases and 44 controls were analyzed. Median (interquartile range) concentrations of TFV-DP at weeks 4 and 8 were 706 (375-1023) fmol/punch and 806 (414-1265) fmol/punch, respectively. Odds ratio (95% confidence interval) for severe adverse pregnancy/neonatal outcome with natural log of TFV-DP concentrations as the predictor were 1.27 (0.74 to 2.18) and 1.74 (0.66 to 4.60) at weeks 4 and 8, respectively. Median (interquartile range) concentrations of FTC-TP at weeks 4 and 8 were 0.27 (0.05-0.36) pmol/punch and 0.29 (0.05-0.40) pmol/punch, respectively. CONCLUSIONS: TFV-DP concentrations in DBS appeared not to be associated with severe adverse pregnancy/neonatal outcomes, although sample size was limited.
Authors: I Marion de Boer; Jan M Prins; Mirjam A G Sprangers; Pythia T Nieuwkerk Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: Sybil G Hosek; Bret Rudy; Raphael Landovitz; Bill Kapogiannis; George Siberry; Brandy Rutledge; Nancy Liu; Jennifer Brothers; Kathleen Mulligan; Gregory Zimet; Michelle Lally; Kenneth H Mayer; Peter Anderson; Jennifer Kiser; James F Rooney; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Kristina M Brooks; Jose R Castillo-Mancilla; Joshua Blum; Ryan Huntley; Samantha MaWhinney; Keisha Alexander; Becky Jo Kerr; Lucas Ellison; Lane R Bushman; Christine E MacBrayne; Peter L Anderson; Jennifer J Kiser Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790
Authors: A Calcagno; D Gonzalez de Requena; M Simiele; A D'Avolio; M C Tettoni; B Salassa; G Orofino; C Bramato; V Libanore; I Motta; P Bigliano; E Orsucci; G Di Perri; S Bonora Journal: Antimicrob Agents Chemother Date: 2013-02-04 Impact factor: 5.191
Authors: J J Kiser; M L Carten; C L Aquilante; P L Anderson; P Wolfe; T M King; T Delahunty; L R Bushman; C V Fletcher Journal: Clin Pharmacol Ther Date: 2007-06-27 Impact factor: 6.875
Authors: Jia-Hua Zheng; Caitlin Rower; Kevin McAllister; Jose Castillo-Mancilla; Brandon Klein; Amie Meditz; L Anthony Guida; Jennifer J Kiser; Lane R Bushman; Peter L Anderson Journal: J Pharm Biomed Anal Date: 2016-01-21 Impact factor: 3.935
Authors: Kristina M Brooks; Jeremiah D Momper; Mauricio Pinilla; Alice M Stek; Emily Barr; Adriana Weinberg; Jaime G Deville; Irma L Febo; Mikhaela Cielo; Kathleen George; Kayla Denson; Kittipong Rungruengthanakit; David E Shapiro; Elizabeth Smith; Nahida Chakhtoura; James F Rooney; Richard Haubrich; Rowena Espina; Edmund V Capparelli; Mark Mirochnick; Brookie M Best Journal: AIDS Date: 2021-03-01 Impact factor: 4.177
Authors: Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick Journal: Expert Opin Drug Metab Toxicol Date: 2020-03-17 Impact factor: 4.936